IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 24 (2008)
Con tacts (Pharm): Chair man: Elena Mitova
Phar ma ceu ti cal Sales: US$ 30-35 mil lion
Prod ucts (% of Sales by Lead ing 5): 55-60%
Ther a peu tic Classes (% of Sales by Lead ing
5): 60-65%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
GLIVEC (antineoplastic other)
ZOMETA (bone cal cium reg u la tor)
FEMARA (cytostatic hor mone an tag o nist)
TRILEPTAL (antiepileptic)
LEPONEX (antipsychotic)
Ther a peu tic Range:
antineoplastics 17%
musculoskeletal drugs other 12%
renin-an gio ten sin sys tem agents 12%
antiepileptics 11%
cytostatic hor mone ther apy 11%
Lead ing Dose Forms:
coated tab lets 30%
tab lets 24%
cap sules 22%
in fu sions 12%
liq uids 5%
SANDOZ
Full Name: Sandoz Pharmaceuticals d.d.
Street Ad dress: Busi ness Park So fia, Build ing 8,
floor 6, 1715 So fia
Tel: +359 2 970 4747
Fax: +359 2 970 4757
De scrip tion: Rep re sen ta tive of fice.
Phar ma ceu ti cal Sales: US$ 22-24 mil lion
Prod ucts (% of Sales by Lead ing 5): 50-55%
Ther a peu tic Classes (% of Sales by Lead ing
5): 70-75%
Dose Forms (% of Sales by Lead ing 5):
80-85%
Prin ci pal Prod ucts:
OSPAMOX (pen i cil lin broad spec trum)
DICLAC (antirheumatic non-steroidal;
antirheumatic top i cal)
AMOKSIKLAV (pen i cil lin broad spec trum)
OSPEXIN (cephalosporin)
LOPEDIUM (mo til ity in hib i tor)
Ther a peu tic Range:
antibacterials sys temic 46%
anti rheu ma tics sys temic 10%
cough and cold prep a ra tions 7%
an ti bi ot ics, sulphonamides and antivirals top i cal
6%
antidiarrheals, elec tro lyte re plac ers, in tes ti nal
anti-inflammatorie s 6%
Lead ing Dose Forms:
coated tab lets 31%
tab lets 22%
cap sules 11%
liq uids 9%
am poules 7%
CANADA
CIBA VI SION
Full Name: CIBA Vi sion Can ada Inc.
Street Ad dress: 2150 Torquay Mews,
Mississauga, On tario, L5N 2M6
Tel: +1 905 821-4774
Fax: +1 905 821-8106
Home Page: www.cibavision.ca
Sub sid iary of: Novartis, Swit zer land (100%)
NOVARTIS
Full Name: Novartis Pharmaceuticals Can ada Inc
Street Ad dress: 385 Bouchard Bou le vard,
Dorval, Que bec, H9S 1A9
Tel: +1 514 631-6775
Fax: +1 514 631-1867
Home Page: www.pharma.ca.novartis.com
De scrip tion: Re searcher, man u fac turer,
packager/as sem bler, im porter, ex porter, dis trib -
u tor, pro moter, sales/detailer. Prod uct ranges in -
clude: phar ma ceu ti cal prod ucts (branded,
pre scrip tion), hos pi tal pharmaceuticals, bio tech -
nol ogy prod ucts. Established 1997.
Con tacts (Pharm): Chair man: Ian Clark; Com -
mer cial Op er a tions: Fran cis Bouchard (Sales),
John Dorsey (Mar ket ing); Man u fac ture: Dr Stan -
ley Brame; Mar ket Re search: Dr Loic Maurel
Par ent of: Novartis Con sumer Health, Can ada
(100%); Novartis Ophthalmics, Can ada (di vi -
sion).
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 620-640 mil lion
Prod ucts (% of Sales by Lead ing 5): 50-55%
Ther a peu tic Classes (% of Sales by Lead ing
5): 60-65%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
DIOVAN (an gio ten sin-II an tag o nist plain)
GLEEVEC (antineoplastic other)
© 2009 IMS Health In cor po rated or its af fil i ates Page 156